Can Diabetes Drugs Metformin and Exenatide Help Bones Heal Faster?

Both metformin and exenatide increased bone cell activity at defect sites in non-diabetic rats, suggesting potential bone healing benefits.

Ozturk, Hasan et al.·Journal of oral and maxillofacial pathology : JOMFP·2025·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-12906Animal StudyPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
N=27
Participants
N=27 female albino Wistar rats with craniotomy defects, divided into metformin, exenatide, and control groups. Non-diabetic.

What This Study Found

Metformin and exenatide significantly increased osteoblast and osteoclast numbers at bone defect sites (p=0.007 for both) without affecting overall bone volume.

Key Numbers

  • 27 rats in 3 groups of 9
  • Metformin dose: 100 mg/kg/day orally
  • Exenatide dose: 3 microg/kg/day intraperitoneally
  • Osteoblast count: significantly higher in both drug groups (p=0.007)
  • Osteoclast count: significantly higher in both drug groups (p=0.007)
  • Bone volume, density, integration: no significant differences

How They Did This

Preclinical study in 27 female Wistar rats with cranial bone defects, analyzed by micro-CT and histology.

Why This Research Matters

If diabetes drugs can enhance bone healing, this could benefit patients with fractures or bone defects, particularly those already taking these medications.

The Bigger Picture

The bone-modulating effects of GLP-1 agonists and metformin add to the growing list of benefits beyond glucose control for these widely used drugs.

What This Study Doesn't Tell Us

Animal study with small groups. No significant difference in bone volume or density. Short observation period.

Questions This Raises

  • ?Would longer treatment show differences in bone volume and density?
  • ?Could these drugs be used clinically to enhance fracture healing?

Trust & Context

Key Stat:
p = 0.007 Significant increase in both osteoblast and osteoclast numbers in drug-treated groups vs. control
Evidence Grade:
Small preclinical study. Interesting but preliminary; no bone volume benefit seen.
Study Age:
Published in 2025.
Original Title:
Osteogenic effects of metformin and exenatide on bone regeneration in non-diabetic rats: A Micro-CT and histological study.
Published In:
Journal of oral and maxillofacial pathology : JOMFP, 29(3), 352-359 (2025)
Database ID:
RPEP-12906

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can diabetes drugs help heal broken bones?

In this rat study, metformin and exenatide increased bone cell activity at defect sites, but actual bone volume was not different from controls. More research is needed.

Does this apply to people who are not diabetic?

The study used non-diabetic rats, suggesting these effects are independent of glucose control, but human studies are needed.

Read More on RethinkPeptides

Cite This Study

RPEP-12906·https://rethinkpeptides.com/research/RPEP-12906

APA

Ozturk, Hasan; Simsek, Neslihan; Akinci, Levent; Ozgocmen, Meltem; Yigit, Dilek Helvacioglu. (2025). Osteogenic effects of metformin and exenatide on bone regeneration in non-diabetic rats: A Micro-CT and histological study.. Journal of oral and maxillofacial pathology : JOMFP, 29(3), 352-359. https://doi.org/10.4103/jomfp.jomfp_4_25

MLA

Ozturk, Hasan, et al. "Osteogenic effects of metformin and exenatide on bone regeneration in non-diabetic rats: A Micro-CT and histological study.." Journal of oral and maxillofacial pathology : JOMFP, 2025. https://doi.org/10.4103/jomfp.jomfp_4_25

RethinkPeptides

RethinkPeptides Research Database. "Osteogenic effects of metformin and exenatide on bone regene..." RPEP-12906. Retrieved from https://rethinkpeptides.com/research/ozturk-2025-osteogenic-effects-of-metformin

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.